Hepatitis B vaccination in haemodialysis patients: A randomized clinical trial

Nephrology

Volumn 14, Issue 3, 2009, Pages 267-272

  Bock, Marilene ^b   Barros, Elvino ^b   Veronese, Francisco J V ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Anti hepatitis B virus surface antigen antibody; End stage kidney disease; Haemodialysis; Hepatitis B; Vaccination

Indexed keywords

HEPATITIS B ANTIBODY; RECOMBINANT HEPATITIS B VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEVER; HEMODIALYSIS; HEPATITIS B; HEPATITIS C; HUMAN; INJECTION SITE PAIN; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; VACCINATION;

ADULT; AGED; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; RENAL DIALYSIS; VACCINATION;

EID: 65349173880     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.01040.x     Document Type: Article

References (39)

1. Burdick RA, Bragg-Gresham JL, Woods JD et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: The DOPPS study. Kidney Int. 2003 63 : 2222 9.
2. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin. Dial. 2005 18 : 52 61.
3. Charest AF, McDougall J, Golstein MB. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am. J. Kidney Dis. 2000 36 : 976 82.
4. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J. Clin. Virol. 2005 34 (Suppl 1 S1 3.
5. Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatellii F. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: A prospective randomized study with cost-effectiveness evaluation. Nephrol. Dial. Transplant. 1997 12 : 1204 11.
6. Waite NM, Thomson MB, Goldstein MB. Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine. J. Am. Soc. Nephrol. 1995 5 : 1930 34.
7. Fernandez E, Betriu MA, Gomez R, Montoliu J. Response to hepatitis B virus vaccine in haemodialysis patients: Influence of malnutrition and its importance as a risk factor for morbidity and mortality. Nephrol. Dial. Transplant. 1996 11 : 1559 63.
8. Sezer S, Ozdemir FN, Guz G et al. Factors influencing response to hepatitis B virus vaccination in hemodialysis patients. Transplant. Proc. 2000 32 : 607 8.
9. Vlasspoulos D. Recombinant hepatitis B vaccination in renal failure patients. Curr. Pharm. Biotechnol. 2003 4 : 141 51.
10. Stenvinkel P. Inflammation in end-stage renal failure: Could it be treated? Nephrol. Dial. Transplant. 2002 17 : 33 8.
11. Schroth RJ, Hitchon CA, Uhanova J et al. Hepatitis B vaccination for patients with chronic renal failure. Cochrane Database Syst. Rev. 2004 3 : CD003775.
12. Mettang T, Schenk U, Thomas S et al. Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure - a preliminary study. Nephron 1997 72 : 192 6.
13. Chanchairujira T, Chantaphakul N, Thanwandee T Efficacy of intradermal hepatitis B vaccination compared to intramuscular vaccination in hemodialysis patients. J. Med. Assoc. Thai. 2006 89 : S33 40.
14. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm. Rep. 2001 50 (RR-5 1 43.
15. Roozbeh J, Moini M, Lankarani KB, Sagheb MM, Shahpoori S, Bastani B. Low dose intradermal versus high dose intramuscular hepatitis B vaccination in patients on chronic hemodialysis. ASAIO J. 2005 51 : 242 5.
16. Vlassopoulos DA, Arvanitis DK, Lilis DS, Louizou KI, Hadjiconstantinou VE. Lower long-term efficiency of intradermal hepatitis B vaccine compared to the intramuscular route in hemodialysis patients. Int. J. Artif. Organs. 1999 22 : 739 43.
17. National Program of Viral Hepatitis, Health Politics Department, Brazilian Ministry of Health. Viral Hepatitis. Brasília : MS, 2003.
18. Center for Disease Control. Hepatitis B virus: Transmission in the United States through universal childhood immunization. Recommendations of the Immunization Practices Advisory Committee. MMWR 1991 40 : 1 25.
19. Daugirdas JT, Van Stone JC. Physiologic principles and urea kinetic modeling. In : Daugirdas JT, Bleke PG, Ing TS (eds). Handbook of Dialysis, 3rd edn. Philadelphia, PA : Lippincott Williams & Wilkins, 2001 15 45.
20. Dinits-Pensy M, Forrest GN, Cross AS, Hise MK. The use of vaccines in adult patients with renal disease. Am. J. Kidney Dis. 2005 46 : 997 1011.
21. Unger JK, Peters H. Hepatitis B in chronic kidney disease: Moving toward effective prevention. Kidney Int. 2008 73 : 799 801.
22. Miller ER, Alter MJ, Tokars JI. Protective effect of hepatitis B vaccine in chronic hemodialysis patients. Am. J. Kidney Dis. 1999 33 : 356 60.
23. Ribot S, Rthstein M, Goldblat M, Grasso M. Duration of hepatitis B surface antigenemia (HBsAg) in hemodialysis patients. Arch. Intern. Med. 1979 139 : 178 80.
24. CDC. Hepatitis: control measures for hepatitis B in dialysis centers. Atlanta, GA : US Department of Health, Education, and Welfare, Public Health Services, CDC, 1977. HEW publication no. (CDC) 78-8358 (Viral Hepatitis Investigations and Control Series).
25. CDC. Recommendations of the Immunization Practices Advisory Committee (ACIP): inactivated hepatitis B virus vaccine. MMWR 1982 31 : 317 22 317 8.
26. Tele SA, Martins RM, Lopes CL, dos Santos Carneiro MA, Souza KP, Yoshida CF. Immunogenicity of recombinant hepatitis B vaccine (Euvax-B) in haemodialysis patients and staff. Eur. J. Epidemiol. 2001 17 : 145 9.
27. Tong NK, Beran J, Kee SA et al. Immunogenicity and safety of an adjuvant hepatitis vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005 68 : 2298 303.
28. Kong NC, Beran J, Kee SA et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int. 2008 73 : 856 62.
29. Mauri JM, Vallés M. Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder chronic uraemic patients. Nephrol. Dial. Transplant. 1997 12 : 729 32.
30. Fabrizi F, Dixit V, Martin P. Meta-analysis the adjuvant role of thymopentin on immunological response to hepatitis B virus vaccine in end-stage renal disease. Aliment. Pharmacol. Ther. 2006 23 : 1559 66.
31. Zuckerman AJ. Appraisal of intradermal immunization against hepatitis B. Lancet 1987 1 : 435 6.
32. Centers for Disease Control. Suboptimal response to hepatitis B vaccine by injection into the buttock. MMWR 1985 34 : 105 13.
33. Chau KF, Cheng YL, Tsang DNC et al. A comparison with the intramuscular vaccination. Am. J. Kidney Dis. 2004 43 : 910 17.
34. Fabrizi F, Dixit V, Magnini M, Elli A, Martin P. Meta-analysis intradermal vs. intramuscular vaccination against hepatitis B virus patients with chronic kidney disease. Aliment. Pharmacol. Ther. 2006 24 : 497 506.
35. Buti M, Viladomiu L, Jardil R et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am. J. Nephrol. 1992 12 : 144 7.
36. West DJ, Calandra GB. Vaccine induced immunologic memory for hepatitis B surface antigen: Implications for policy on booster vaccination. Vaccine 1996 14 : 1019 27.
37. Peces R, Torre M, Alcaza R, Urra JM. Prospective Analysis of the Factors Influencing the Antibody Response to Hepatitis B Vaccine in Hemodialysis Patients. Am. J. Kidney Dis. 1997 29 : 239 45.
38. Kovacic V, Sain M, Vukman V. Efficient haemodialysis improves the response to hepatitis B virus vaccination. Intervirology 2002 45 : 172 6.
39. Navarro JF, Terruel JL, Mateos M, Ortuno J. Antibody level after hepatitis B vaccination in hemodialysis patients: Influence of hepatitis C virus infection. Am. J. Nephrol. 1996 16 : 95 7.